BioSpace News Archive

BioNTech SE and OncoC4, Inc., announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody candidate, BNT316/ONC-392, in a patient cohort with metastatic, PD-1-resistant non-small cell lung cancer.

WELL Health Technologies Corp. is pleased to announce that a team from WELL Health including Hamed Shahbazi , Founder and CEO, will be participating in the Eight Capital innoVIII: AI: Theory to Commerciality Conference (the “Conference”) in Montreal.

Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference.

Bruker Corporation (Nasdaq: BRKR) announced today it will present at the Jefferies 2023 Healthcare Conference in New York on Friday, June 9, 2023 at 9:00 am EDT.

Capsida Biotherapeutics (“Capsida”) today announced it will present new preclinical data showing the potential for its engineered adeno-associated virus (AAV) therapeutics to treat genetic epilepsy caused by mutations in the syntaxin-binding protein 1 (STXBP1) gene.

Black Diamond Therapeutics, Inc. announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company’s MasterKey programs, including BDTX-1535 and BDTX-4933, at the Jefferies Healthcare Conference on Friday, June 9, 2023, at 12:45 p.m. ET in New York, NY.

TRACON Pharmaceuticals, Inc. announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 8:30 am Eastern Time.

Adverum Biotechnologies, Inc. today announced that Laurent Fischer, M.D., president and chief executive officer will present at the Jefferies Healthcare Conference on Friday, June 9, 2023 at 10:00 a.m. ET in New York, New York.

Eledon Pharmaceuticals, Inc. today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will present a company overview at the upcoming Jefferies Healthcare Conference on Friday, June 9, 2023, at 9:00 a.m. ET.

Immutep Limited is pleased to announce the successful completion of an institutional placement and the institutional component of its 1 for 7.6 pro rata accelerated non-renounceable entitlement offer of new fully paid ordinary shares in Immutep.